Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (582)

« Back to Publications

Implicit learning across varying temporal scales in individuals with and without mood instability.

Atkinson LZ. et al, (2026), J Affect Disord, 395

Cost-effectiveness of pramipexole augmentation for acute phase and maintenance therapy of treatment-resistant depression compared to placebo augmentation: economic evaluation of the PAX-D randomised controlled trial.

Łaszewska A. et al, (2026), Lancet Reg Health Eur, 61

Anthropomorphic technology in everyday life: focus on chatbots and impacts on mental health.

Monteith S. et al, (2026), Eur Arch Psychiatry Clin Neurosci, 276, 391 - 397

Increasing use of generative artificial intelligence by teenagers.

Monteith S. et al, (2026), Br J Psychiatry, 1 - 3

Artificial intelligence and deskilling in medicine.

Monteith S. et al, (2026), Br J Psychiatry, 1 - 3

Impact of Long-Acting Injectable Versus Oral Antipsychotic Treatment on All-Cause Discontinuation Risk in People with Early Phase Schizophrenia and Comorbid Substance Use Disorder: A Secondary Analysis of the EULAST Randomized Trial.

Mortazavi M. et al, (2026), CNS Drugs, 40, 99 - 109

Cost-effectiveness of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression: Economic evaluation of the PAX-BD randomised controlled trial.

Berger M. et al, (2025), J Affect Disord, 391

Importance of patient online activities.

Monteith S. et al, (2025), Br J Psychiatry, 227, 718 - 720

Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK.

Browning M. et al, (2025), Lancet Psychiatry, 12, 579 - 589

Personality disorders, violence and antisocial behaviour: updated systematic review and meta-regression analysis.

Chow RTS. et al, (2025), Br J Psychiatry, 227, 481 - 491

Neural signatures of risk-taking adaptions across health, bipolar disorder, and lithium treatment.

Scholl J. et al, (2025), Mol Psychiatry, 30, 2955 - 2965

The value of mental science: we publish what matters.

Malhi GS. et al, (2025), Br J Psychiatry, 227, 429 - 433

Reducing inequalities through greater diversity in clinical trials - As important for medical devices as for drugs and therapeutics.

Roope LSJ. et al, (2025), Contemp Clin Trials Commun, 45

Patient and Physician Exposure to Artificial Intelligence Hype.

Monteith S. et al, (2025), Pharmacopsychiatry

Effect of lithium on circadian activity level and flexibility in patients with bipolar disorder: results from the Oxford Lithium Trial.

Xu N. et al, (2025), EBioMedicine, 115

Load More

1
2
3
4
5
6
7
...
»